Next Article in Journal
Radiomics Prediction of EGFR Status in Lung Cancer—Our Experience in Using Multiple Feature Extractors and The Cancer Imaging Archive Data
Previous Article in Journal
Lung Nodule Sizes Are Encoded When Scaling CT Image for CNN's
Tomography is published by MDPI from Volume 7 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Grapho, LLC.
Article

Tumor Sphericity Predicts Response in Neoadjuvant Chemotherapy for Invasive Breast Cancer

1
Department of Radiology & Biomedical Imaging, University of California, UCSF Mt Zion Medical Center, 1600 Divisadero Street Box 1667, San Francisco, CA 94115, USA
2
Department of Radiology, Seoul National University Bundang Hospital, Seoul, Korea
3
Departments of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA
4
Departments of Surgery, University of California, San Francisco, CA, USA
*
Author to whom correspondence should be addressed.
Tomography 2020, 6(2), 216-222; https://doi.org/10.18383/j.tom.2020.00016
Received: 9 March 2020 / Revised: 8 April 2020 / Accepted: 6 May 2020 / Published: 1 June 2020
This retrospective study examined magnetic resonance imaging (MRI)–derived tumor sphericity (SPH) as a quantitative measure of breast tumor morphology, and investigated the association between SPH and reader-assessed morphological pattern (MP). In addition, association of SPH with pathologic complete response was evaluated in patients enrolled in an adaptively randomized clinical trial designed to rapidly identify new agents for breast cancer. All patients underwent MRI examinations at multiple time points during the treatment. SPH values from pretreatment (T0) and early-treatment (T1) were investigated in this study. MP on T0 dynamic contrast-enhanced MRI was ranked from 1 to 5 in 220 patients. Mean SPH values decreased with the increased order of MP. SPH was higher in patients with pathologic complete response than in patients without (difference at T0: 0.04, 95% confidence interval [CI]: 0.02–0.05, P < .001; difference at T1: 0.03, 95% CI: 0.02–0.04, P < .001). The area under the receiver operating characteristic curve was estimated as 0.61 (95% CI, 0.57–0.65) at T0 and 0.58 (95% CI, 0.55–0.62) at T1. When the analysis was performed by cancer subtype defined by hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) status, highest area under the receiver operating characteristic curve were observed in HR−/HER2+: 0.67 (95% CI, 0.54–0.80) at T0, and 0.63 (95% CI, 0.51–0.76) at T1. Tumor SPH showed promise to quantify MRI MPs and as a biomarker for predicting treatment outcome at pre- or early-treatment time points.
Keywords: sphericity; magnetic resonance imaging; breast cancer; neoadjuvant therapy sphericity; magnetic resonance imaging; breast cancer; neoadjuvant therapy
MDPI and ACS Style

Li, W.; Newitt, D.C.; La Yun, B.; Jones, E.F.; Arasu, V.; Wilmes, L.J.; Gibbs, J.; Nguyen, A.A.-T.; Onishi, N.; Kornak, J.; Joe, B.N.; Esserman, L.J.; Hylton, N.M. Tumor Sphericity Predicts Response in Neoadjuvant Chemotherapy for Invasive Breast Cancer. Tomography 2020, 6, 216-222. https://doi.org/10.18383/j.tom.2020.00016

AMA Style

Li W, Newitt DC, La Yun B, Jones EF, Arasu V, Wilmes LJ, Gibbs J, Nguyen AA-T, Onishi N, Kornak J, Joe BN, Esserman LJ, Hylton NM. Tumor Sphericity Predicts Response in Neoadjuvant Chemotherapy for Invasive Breast Cancer. Tomography. 2020; 6(2):216-222. https://doi.org/10.18383/j.tom.2020.00016

Chicago/Turabian Style

Li, Wen, David C. Newitt, Bo La Yun, Ella F. Jones, Vignesh Arasu, Lisa J. Wilmes, Jessica Gibbs, Alex Anh-Tu Nguyen, Natsuko Onishi, John Kornak, Bonnie N. Joe, Laura J. Esserman, and Nola M. Hylton 2020. "Tumor Sphericity Predicts Response in Neoadjuvant Chemotherapy for Invasive Breast Cancer" Tomography 6, no. 2: 216-222. https://doi.org/10.18383/j.tom.2020.00016

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop